IONIS FB LRx
Alternative Names: RO-7434656; ASO Factor B; IONIS-FB-LRx; IONIS-FB-LRX; ISIS-696844; RG-6299Latest Information Update: 16 Aug 2024
At a glance
- Originator Ionis Pharmaceuticals
- Developer Ionis Pharmaceuticals; Roche
- Class Antisense oligonucleotides; Eye disorder therapies
- Mechanism of Action Complement factor B expression inhibitors; Gene silencing
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III IgA nephropathy
- Discontinued Age-related macular degeneration
Most Recent Events
- 16 Aug 2024 Discontinued - Phase-II for Age-related macular degeneration (In the elderly, In adults) in Spain, Poland, Netherlands, Czech Republic, Canada, Austria, New Zealand, USA, Australia (SC) (Roche pipeline, August 2024)
- 12 Jun 2024 Ionis Pharmaceuticals completes the phase II GOLDEN trial in Age-related macular degeneration in USA, Australia, Austria, Canada, Czech Republic, Netherlands, New Zealand, Poland and Spain (SC) (NCT03815825)
- 09 May 2024 Roche plans to file regulatory filing for IgA nephropathy, in or after 2027 (Roche pipeline, May 2024)